HUE060060T2 - Kataplexia kezelése - Google Patents

Kataplexia kezelése

Info

Publication number
HUE060060T2
HUE060060T2 HUE14778088A HUE14778088A HUE060060T2 HU E060060 T2 HUE060060 T2 HU E060060T2 HU E14778088 A HUE14778088 A HU E14778088A HU E14778088 A HUE14778088 A HU E14778088A HU E060060 T2 HUE060060 T2 HU E060060T2
Authority
HU
Hungary
Prior art keywords
cataplexy
treatment
Prior art date
Application number
HUE14778088A
Other languages
English (en)
Inventor
Moise A Khayrallah
Gary Bream
Stephen E Butts
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51530017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE060060(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Ireland Ltd, Sk Biopharmaceuticals Co Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of HUE060060T2 publication Critical patent/HUE060060T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • A61K31/025Halogenated hydrocarbons carbocyclic
    • A61K31/03Halogenated hydrocarbons carbocyclic aromatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/02Carbamic acids; Salts of carbamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HUE14778088A 2013-03-13 2014-03-12 Kataplexia kezelése HUE060060T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361778998P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
HUE060060T2 true HUE060060T2 (hu) 2023-01-28

Family

ID=51530017

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14778088A HUE060060T2 (hu) 2013-03-13 2014-03-12 Kataplexia kezelése

Country Status (22)

Country Link
US (6) US9359290B2 (hu)
EP (1) EP2968208B1 (hu)
JP (2) JP6530741B2 (hu)
KR (1) KR102192554B1 (hu)
CN (1) CN105431142B (hu)
AU (1) AU2014248849B2 (hu)
BR (1) BR112015022197B1 (hu)
CA (1) CA2905457A1 (hu)
DK (1) DK2968208T3 (hu)
ES (1) ES2927675T3 (hu)
HK (1) HK1219236A1 (hu)
HR (1) HRP20221018T1 (hu)
HU (1) HUE060060T2 (hu)
MX (1) MX2015012644A (hu)
MY (1) MY177740A (hu)
PH (1) PH12015502075B1 (hu)
PT (1) PT2968208T (hu)
RU (2) RU2689984C2 (hu)
SG (1) SG11201507121RA (hu)
SI (1) SI2968208T1 (hu)
TW (2) TWI684450B (hu)
WO (1) WO2014164969A1 (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101335941B1 (ko) * 2005-06-08 2013-12-04 에스케이바이오팜 주식회사 수면-각성 장애의 치료
WO2011005473A2 (en) 2009-06-22 2011-01-13 Shionogi Pharma, Inc. Methods for treating or preventing fatigue
JP6530741B2 (ja) * 2013-03-13 2019-06-12 エアリアル,バイオファーマ,エルエルシー カタプレキシーの治療
DK3021838T3 (da) 2013-07-18 2020-08-24 Jazz Pharmaceuticals Ireland Ltd Behandling af fedme
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
KR102513800B1 (ko) 2016-09-06 2023-03-24 에스케이바이오팜 주식회사 (r)-2-아미노-3-페닐프로필 카바메이트의 용매화물 폼
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
KR102616545B1 (ko) * 2016-10-06 2023-12-26 재즈 파마슈티칼즈 아일랜드 리미티드 카바모일 페닐알라닌올 화합물 및 이의 용도
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
CA3071779A1 (en) 2017-07-31 2019-02-07 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol analogs and uses thereof
WO2019055369A1 (en) * 2017-09-12 2019-03-21 Ovid Therapeutics Inc. USE OF GABOXADOL IN THE TREATMENT OF NARCOLEPSIA
WO2019148181A1 (en) 2018-01-29 2019-08-01 Cognos Therapeutics, Inc. Intratumoral delivery of bortezomib
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
MX2021004207A (es) * 2018-10-15 2021-08-11 Axsome Therapeutics Inc Uso de reboxetina para el tratamiento de narcolepsia.
US20200147093A1 (en) * 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
IL293536A (en) * 2019-12-03 2022-08-01 Axsome Therapeutics Inc Use of reboxetine to treat disease states in the nervous system
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US178429A (en) * 1876-06-06 Improvement in hulling-machines
JPS58156351A (ja) * 1982-03-11 1983-09-17 Sumitomo Chem Co Ltd メタクリル酸合成触媒の再生方法
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
ES2170878T3 (es) 1996-10-10 2002-08-16 Sk Corp Compuestos de o-carbamoil-fenilalaninol y sus sales farmaceuticamente utiles.
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
GB0109103D0 (en) * 2001-04-11 2001-05-30 Pfizer Ltd Novel compounds
US20030207857A1 (en) 2001-04-11 2003-11-06 Adam Mavis D. Phenyl heterocyclyl ethers
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
WO2005096734A2 (en) 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine h3 receptor modulators
JP2008512386A (ja) * 2004-09-07 2008-04-24 オーファン メディカル,インコーポレイティド 改良型ghb組成物
MX2007005172A (es) 2004-10-28 2007-06-22 Sk Corp Terapia adjunta para la depresion.
KR101335941B1 (ko) * 2005-06-08 2013-12-04 에스케이바이오팜 주식회사 수면-각성 장애의 치료
EP1893291B1 (en) 2005-06-22 2010-03-03 SK Holdings Co., Ltd. Treatment of sexual dysfunction
ATE538784T1 (de) 2005-07-26 2012-01-15 Sk Biopharmaceuticals Co Ltd Verfahren zur behandlung von substanzbedingten erkrankungen
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
MX2009003926A (es) 2006-10-13 2009-06-26 Janssen Pharmaceutica Nv Composiciones de fenilalquilamino-carbamato.
CA2669185A1 (en) * 2006-11-10 2008-05-15 Dimerix Bioscience Pty Ltd Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers
WO2011005473A2 (en) 2009-06-22 2011-01-13 Shionogi Pharma, Inc. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
AU2010316106B2 (en) 2009-11-06 2015-10-22 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
MX350745B (es) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
JP6530741B2 (ja) * 2013-03-13 2019-06-12 エアリアル,バイオファーマ,エルエルシー カタプレキシーの治療

Also Published As

Publication number Publication date
BR112015022197A8 (pt) 2019-11-26
US20140275244A1 (en) 2014-09-18
ES2927675T3 (es) 2022-11-10
WO2014164969A1 (en) 2014-10-09
US10259780B2 (en) 2019-04-16
AU2014248849A1 (en) 2015-10-08
RU2689984C2 (ru) 2019-05-30
HK1219236A1 (zh) 2017-03-31
SI2968208T1 (sl) 2023-02-28
US20190218174A1 (en) 2019-07-18
US20160250176A1 (en) 2016-09-01
US9359290B2 (en) 2016-06-07
CN105431142B (zh) 2019-04-26
KR20150139522A (ko) 2015-12-11
US20170137375A1 (en) 2017-05-18
EP2968208A1 (en) 2016-01-20
TWI684450B (zh) 2020-02-11
MY177740A (en) 2020-09-23
DK2968208T3 (da) 2022-08-22
EP2968208B1 (en) 2022-07-20
BR112015022197B1 (pt) 2022-06-07
PH12015502075A1 (en) 2016-01-18
CA2905457A1 (en) 2014-10-09
US20220017457A1 (en) 2022-01-20
JP6530741B2 (ja) 2019-06-12
RU2019114940A (ru) 2019-06-28
HRP20221018T1 (hr) 2023-01-06
KR102192554B1 (ko) 2020-12-18
MX2015012644A (es) 2016-06-21
EP2968208A4 (en) 2016-10-12
PH12015502075B1 (en) 2016-01-18
AU2014248849B2 (en) 2018-08-30
TWI663971B (zh) 2019-07-01
TW201513856A (zh) 2015-04-16
RU2015143610A3 (hu) 2018-03-21
RU2015143610A (ru) 2017-04-20
PT2968208T (pt) 2022-10-28
RU2019114940A3 (hu) 2019-12-25
BR112015022197A2 (pt) 2017-07-18
US11713292B2 (en) 2023-08-01
SG11201507121RA (en) 2015-10-29
CN105431142A (zh) 2016-03-23
US9585863B2 (en) 2017-03-07
US20230416195A1 (en) 2023-12-28
TW201919606A (zh) 2019-06-01
JP2016512531A (ja) 2016-04-28
JP2019147830A (ja) 2019-09-05
US11072579B2 (en) 2021-07-27

Similar Documents

Publication Publication Date Title
HK1219236A1 (zh) 猝倒的治療
IL287516A (en) Medicinal uses of empagliflozin
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
HK1213818A1 (zh) 依帕列淨的治療用途
SI2981271T1 (sl) Terapevtske uporabe empagliflozina
HK1224324A1 (zh) 煤處理
HK1188366A2 (en) One type of massager
IL241096B (en) Treatment methods
GB201607581D0 (en) Treatment of cancer
HK1232118A1 (zh) 癌症的治療
ZA201601626B (en) Treatment of gases
GB201314303D0 (en) Treatment of HPV
GB201320653D0 (en) Treatment of plants
GB201322347D0 (en) Treatment of cancer
GB201318742D0 (en) Treatment of cancer
GB201322778D0 (en) Method of treatment
GB201308529D0 (en) Treatment of cancer
GB201314882D0 (en) Method of treatment
GB201305020D0 (en) Treatment of cancer